Clinical trial registry record

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 29, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04423718
Last registry update
August 29, 2025
Status
Completed
Phase
Phase 3
Sponsor
Bayer
Enrollment
1011
Countries
United States, Argentina, Australia, Austria, Bulgaria, Canada, China, Czechia, Estonia, France, Georgia, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Portugal, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Switzerland, Taiwan, Ukraine
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
1011
Population
ALL · 50 Years
Duration
2020-08-11 to 2024-08-07
Intervention
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321); Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Comparator
Aflibercept 2q8
Outcomes measured
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — At baseline and Week 48; Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 60 — At baseline and Week 60; Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in Central Subfield at Week 1…; Percentage of Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 48 — At baseline and Week 48; Percentage of Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Wee…; Change in Choroidal Neovascularization (CNV) Size From Baseline to Week 48 — At baseline and Week 48; Change in Total Lesion Area From Baseline to Week 48 — At baseline and Week 48; Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in the Center Subfield at Wee…; Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 48 — At baseline and Week 48; Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Total Score at Week 48…; Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept Fro…; Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response — Up to week 96
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON